Refining criteria for a neurodevelopmental sub-phenotype of bipolar disorders: a FondaMental Advanced Centers of Expertise for Bipolar Disorders study.

Neurodevelopment bipolar disorder genomics lithium response neurological soft sign stratification

Journal

Biological psychiatry
ISSN: 1873-2402
Titre abrégé: Biol Psychiatry
Pays: United States
ID NLM: 0213264

Informations de publication

Date de publication:
10 Oct 2024
Historique:
received: 22 03 2024
revised: 03 09 2024
accepted: 25 09 2024
medline: 13 10 2024
pubmed: 13 10 2024
entrez: 12 10 2024
Statut: aheadofprint

Résumé

Bipolar disorder (BD) is a complex and heterogeneous psychiatric disorder. Neurodevelopmental factors were suggested to contribute to the etiology of BD, yet a specific neurodevelopmental phenotype of the disorder remains unidentified. Our objective was to define and characterize a neurodevelopmental phenotype (NDP) in BD and validate its associations with clinical outcomes, polygenic risk scores (PGS), and treatment responses. We analyzed the FACE-BD cohort of 4,468 BD patients, a validation cohort of 101 BD patients, and two independent replication datasets of 274 and 89 BD patients. Using factor analyses, we identified a set of criteria for defining NDP. We next developed a scoring system for NDP-load and assessed its association with prognosis, neurological soft signs, polygenic risk scores for neurodevelopmental disorders, and responses to treatment using multiple regressions, adjusted for age and sex with bootstrap replications. Our study established a NDP in BD consisting of nine clinical features: advanced paternal age, advanced maternal age, childhood maltreatment, attention deficit hyperactivity disorder (ADHD), early onset of BD, early onset of substance use disorders, early onset of anxiety disorders, early onset of eating disorders, specific learning disorders. Patients with higher NDP-load showed a worse prognosis and increased neurological soft signs. Notably, these individuals exhibited a poorer response to lithium treatment. Furthermore, a significant positive correlation was observed between the NDP-load and PGS for ADHD suggesting potential overlapping genetic factors or pathophysiological mechanisms between BD and ADHD. The proposed NDP constitutes a promising clinical tool for patient stratification in BD.

Sections du résumé

BACKGROUND BACKGROUND
Bipolar disorder (BD) is a complex and heterogeneous psychiatric disorder. Neurodevelopmental factors were suggested to contribute to the etiology of BD, yet a specific neurodevelopmental phenotype of the disorder remains unidentified. Our objective was to define and characterize a neurodevelopmental phenotype (NDP) in BD and validate its associations with clinical outcomes, polygenic risk scores (PGS), and treatment responses.
METHOD METHODS
We analyzed the FACE-BD cohort of 4,468 BD patients, a validation cohort of 101 BD patients, and two independent replication datasets of 274 and 89 BD patients. Using factor analyses, we identified a set of criteria for defining NDP. We next developed a scoring system for NDP-load and assessed its association with prognosis, neurological soft signs, polygenic risk scores for neurodevelopmental disorders, and responses to treatment using multiple regressions, adjusted for age and sex with bootstrap replications.
RESULTS RESULTS
Our study established a NDP in BD consisting of nine clinical features: advanced paternal age, advanced maternal age, childhood maltreatment, attention deficit hyperactivity disorder (ADHD), early onset of BD, early onset of substance use disorders, early onset of anxiety disorders, early onset of eating disorders, specific learning disorders. Patients with higher NDP-load showed a worse prognosis and increased neurological soft signs. Notably, these individuals exhibited a poorer response to lithium treatment. Furthermore, a significant positive correlation was observed between the NDP-load and PGS for ADHD suggesting potential overlapping genetic factors or pathophysiological mechanisms between BD and ADHD.
CONCLUSIONS CONCLUSIONS
The proposed NDP constitutes a promising clinical tool for patient stratification in BD.

Identifiants

pubmed: 39395474
pii: S0006-3223(24)01654-8
doi: 10.1016/j.biopsych.2024.09.025
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Antoine Lefrere (A)

Pôle de Psychiatrie, Assistance Publique Hôpitaux de Marseille, Marseille, France; Institut de Neurosciences de la Timone, Aix-Marseille Univ, UMR CNRS, France; Fondation Fondamental, F-94010, Créteil, France.

Ophélia Godin (O)

Univ Paris Est Créteil, INSERM, IMRB, Translational Neuro-Psychiatry, AP-HP, DMU IMPACT, FHU ADAPT, Fondation Fondamental, F-94010; Fondation Fondamental, F-94010, Créteil, France.

Stéphane Jamain (S)

Univ Paris Est Créteil, INSERM, IMRB, Translational Neuro-Psychiatry, AP-HP, DMU IMPACT, FHU ADAPT, Fondation Fondamental, F-94010; Fondation Fondamental, F-94010, Créteil, France.

Yecodji Dansou (Y)

Fondation Fondamental, F-94010, Créteil, France; Fondation Fondamental, F-94010, Créteil, France.

Ludovic Samalin (L)

Department of Psychiatry, CHU Clermont-Ferrand, University of Clermont Auvergne, CNRS, Clermont Auvergne INP, Institut Pascal (UMR 6602), Clermont-Ferrand, France; Fondation Fondamental, F-94010; Fondation Fondamental, F-94010, Créteil, France.

Martin Alda (M)

Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada; National Institute of Mental Health, Klecany, Czech Republic.

Bruno Aouizerate (B)

Centre Hospitalier Charles Perrens, Laboratoire NutriNeuro (UMR INRA 1286), Université de Bordeaux, Bordeaux, France; Fondation Fondamental, F-94010; Fondation Fondamental, F-94010, Créteil, France.

Valérie Aubin (V)

Pôle de Psychiatrie, Centre Hospitalier Princesse Grace, Monaco; Fondation Fondamental, F-94010, Créteil, France; Fondation Fondamental, F-94010, Créteil, France.

Romain Rey (R)

Bipolar Disorder Expert Centre, Le Vinatier Hospital, Bron; University Lyon 1, Villeurbanne; INSERM, U1028; CNRS, UMR5292; Lyon Neuroscience Research Center, Psychiatric Disorders, Neuroscience Research and Clinical Research Team, Lyon, F-69000, France; Fondation Fondamental, F-94010, Créteil, France.

Martina Contu (M)

Section of Psychiatry, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.

Philippe Courtet (P)

CHU Montpellier, Hôpital Lapeyronie, Psychiatric Emergency and Post Emergency Department, Pole Urgence; IGF, Université de Montpellier, CNRS, INSERM, Montpellier, France; Fondation Fondamental, F-94010, Créteil, France; Fondation Fondamental, F-94010, Créteil, France.

Caroline Dubertret (C)

AP-HP, Groupe Hospitalo-Universitaire AP-HP Nord, DMU ESPRIT, Service de Psychiatrie et Addictologie, Hôpital Louis Mourier, Colombes, France; Université de Paris, Inserm UMR1266, Sorbonne Paris Cité, Faculté de Médecine, Paris, France; Fondation Fondamental, F-94010, Créteil, France; Fondation Fondamental, F-94010, Créteil, France.

Emmanuel Haffen (E)

Service de Psychiatrie de l'Adulte, CIC-1431 INSERM, CHU de Besançon, Laboratoire de Neurosciences, UFC, UBFC, Besançon, France; Fondation Fondamental, F-94010, Créteil, France; Fondation Fondamental, F-94010, Créteil, France.

Dominique Januel (D)

Unité de Recherche Clinique, EPS Ville-Evrard, 93332 Neuilly-sur-Marne, France; Fondation Fondamental, F-94010, Créteil, France; Fondation Fondamental, F-94010, Créteil, France.

Marion Leboyer (M)

Univ Paris Est Créteil, INSERM, IMRB, Translational Neuro-Psychiatry, AP-HP, DMU IMPACT, FHU ADAPT, Fondation Fondamental, F-94010; Fondation Fondamental, F-94010, Créteil, France.

Pierre Michel Llorca (PM)

Department of Psychiatry, CHU Clermont-Ferrand, University of Clermont Auvergne, CNRS, Clermont Auvergne INP, Institut Pascal (UMR 6602), Clermont-Ferrand, France; Fondation Fondamental, F-94010; Fondation Fondamental, F-94010, Créteil, France.

Emeline Marlinge (E)

GHU Paris Nord, DMU Neurosciences, Hôpital Fernand Widal AP-HP, Paris, France; Fondation Fondamental, F-94010, Créteil, France; Fondation Fondamental, F-94010, Créteil, France.

Mirko Manchia (M)

Section of Psychiatry, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.

Samantha Neilson (S)

Institut de Neurosciences de la Timone, Aix-Marseille Univ, UMR CNRS, France.

Emilie Olié (E)

CHU Montpellier, Hôpital Lapeyronie, Psychiatric Emergency and Post Emergency Department, Pole Urgence; IGF, Université de Montpellier, CNRS, INSERM, Montpellier, France; Fondation Fondamental, F-94010, Créteil, France; Fondation Fondamental, F-94010, Créteil, France.

Pasquale Paribello (P)

Lucio Bini Mood Disorder Centers, Cagliari, Italy.

Marco Pinna (M)

Section of Psychiatry, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy; Lucio Bini Mood Disorder Centers, Cagliari, Italy.

Mircea Polosan (M)

Université Grenoble Alpes, Inserm, U1216, CHU Grenoble Alpes, Grenoble Institut Neurosciences, Grenoble, France; Fondation Fondamental, F-94010, Créteil, France; Fondation Fondamental, F-94010, Créteil, France.

Paul Roux (P)

Centre Hospitalier de Versailles, Service Hospitalo-Universitaire de Psychiatrie d'Adultes et d'Addictologie, Le Chesnay; Université Paris-Saclay; Université de Versailles Saint-Quentin-En-Yvelines; DisAP-DevPsy-CESP, INSERM UMR1018, Villejuif, France; Fondation Fondamental, F-94010, Créteil, France; Fondation Fondamental, F-94010, Créteil, France.

Raymund Schwan (R)

Université de Lorraine, Centre Psychothérapique de Nancy, Inserm U1254, Nancy, France; Fondation Fondamental, F-94010, Créteil, France; Fondation Fondamental, F-94010, Créteil, France.

Leonardo Tondo (L)

Lucio Bini Mood Disorder Centers, Cagliari and Rome, Italy; International Consortium for Mood & Psychotic Disorders Research, Mailman Research Center, McLean Hospital, Belmont, MA, USA; Department of Psychiatry, Harvard Medical School, Boston, MA, USA.

Michel Walter (M)

Service Hospitalo-Universitaire de Psychiatrie Générale et de Réhabilitation Psycho Sociale 29G01 et 29G02, CHRU de Brest, Hôpital de Bohars, Brest, France; Fondation Fondamental, F-94010, Créteil, France; Fondation Fondamental, F-94010, Créteil, France.

Eleni Tzavara (E)

Université Paris Cité, 75005 Paris, France; CNRS, UMR 8002, 75006 Paris, France; Pôle de Psychiatrie, Assistance Publique Hôpitaux de Marseille, Marseille, France.

Guillaume Auzias (G)

Institut de Neurosciences de la Timone, Aix-Marseille Univ, UMR CNRS, France.

Christine Deruelle (C)

Institut de Neurosciences de la Timone, Aix-Marseille Univ, UMR CNRS, France.

Bruno Etain (B)

Univ Paris Est Créteil, INSERM, IMRB, Translational Neuro-Psychiatry, AP-HP, DMU IMPACT, FHU ADAPT, Fondation Fondamental, F-94010; Fondation Fondamental, F-94010, Créteil, France.

Raoul Belzeaux (R)

CHU Montpellier, Hôpital Lapeyronie, Psychiatric Emergency and Post Emergency Department, Pole Urgence; IGF, Université de Montpellier, CNRS, INSERM, Montpellier, France; Fondation Fondamental, F-94010, Créteil, France; Fondation Fondamental, F-94010, Créteil, France. Electronic address: raoul.belzeaux@chu-montpellier.fr.

Classifications MeSH